The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading ->
The African content is one step closer to its first medicine and health super-regulator. The treaty to establish an African Medicine Agency (AMA), meant to govern medical product regulation for the entire continent, was endorsed by the African Union Heads of State and Government on 11 February, according to a press release following the 32nd AU Summit in Addis Ababa, Ethiopia. Continue reading ->
Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading ->
Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading ->
Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading ->